Cancer

Cover image for Vol. 120 Issue 12

15 June 2014

Volume 120, Issue 12

Pages 1755–1910

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Commentary

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Silent diffuse low-grade glioma: Toward screening and preventive treatment? (pages 1758–1762)

      Emmanuel Mandonnet, Philip de Witt Hamer, Johan Pallud, Luc Bauchet, Ian Whittle and Hugues Duffau

      Article first published online: 11 MAR 2014 | DOI: 10.1002/cncr.28610

      We show that people with a silent glioma have more chances to die from their gliomas than from another unrelated cause. This result, combined with the knowledge that diffuse low-grade gliomas remain clinically silent for a very long period (>10 years), grounds the screening and preventive treatment of silent diffuse low-grade glioma.

  3. Review Article

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone (pages 1763–1774)

      Leona A. Doyle

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28657

      Since the publication of the prior World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone 11 years ago, new clinicopathologic and genetic features of many soft tissue and bone tumors have been characterized, allowing obsolete diagnostic categories to be removed and new tumor types to be added. This article reviews the changes in the 2013 WHO classification, along with new genetic data that have emerged even since the publication of the current volume.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Disease Site

      Breast Disease
      Expression of androgen receptor in inflammatory breast cancer and its clinical relevance (pages 1775–1779)

      Yun Gong, Wei Wei, Yun Wu, Naoto T. Ueno and Lei Huo

      Article first published online: 13 MAR 2014 | DOI: 10.1002/cncr.28667

      Androgen receptor is commonly expressed in inflammatory breast cancer. Patients who have inflammatory breast cancer with androgen receptor-negative/estrogen receptor-negative tumors have significantly worse clinical outcomes than patients who have tumors that exhibit other combinations of androgen receptor/estrogen receptor status.

    2. Gastrointestinal Disease
      Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab (pages 1780–1786)

      Shubham Pant, Ludmila K. Martin, Susan Geyer, Lai Wei, Katherine Van Loon, Nilli Sommovilla, Mark Zalupski, Renuka Iyer, David Fogelman, Andrew H. Ko and Tanios Bekaii-Saab

      Article first published online: 13 MAR 2014 | DOI: 10.1002/cncr.28648

      Patients with advanced pancreatic cancer with normal baseline serum albumin levels appear to derive benefit from bevacizumab. Future prospective investigations of bevacizumab in the treatment of advanced pancreatic cancer should consider selecting patients with normal baseline serum albumin to maximize potential benefit.

    3. Genitourinary Disease
      The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease (pages 1787–1793)

      Florence K. Keane, Ming-Hui Chen, Danjie Zhang, Marian J. Loffredo, Philip W. Kantoff, Andrew A. Renshaw and Anthony V. D'Amico

      Article first published online: 6 MAR 2014 | DOI: 10.1002/cncr.28609

      The lack of prostate cancer (PC) deaths among men with favorable intermediate-risk PC suggests that adding androgen-suppression therapy may not reduce their risk of PC-specific mortality; whereas many men with unfavorable intermediate-risk PC are at increased risk for harboring occult PC with Gleason scores from 8 to 10 and may benefit from long-term androgen-suppression therapy. Multiparametric magnetic resonance imaging and targeted biopsy of suspicious lesions should be considered to identify occult PC with Gleason scores from 8 to 10 in these men.

    4. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma (pages 1794–1799)

      Sima Porten, Arlene O. Siefker-Radtke, Lianchun Xiao, Vitaly Margulis, Ashish M. Kamat, Christopher G. Wood, Eric Jonasch, Colin P. N. Dinney and Surena F. Matin

      Article first published online: 13 MAR 2014 | DOI: 10.1002/cncr.28655

      Neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma compared with a matched historic cohort of patients treated with initial surgery.

    5. Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors (pages 1800–1809)

      Anthony E. Rizzardi, Rachel Isaksson Vogel, Joseph S. Koopmeiners, Colleen L. Forster, Lauren O. Marston, Nikolaus K. Rosener, Natalia Akentieva, Matthew A. Price, Gregory J. Metzger, Christopher A. Warlick, Jonathan C. Henriksen, Eva A. Turley, James B. McCarthy and Stephen C. Schmechel

      Article first published online: 25 MAR 2014 | DOI: 10.1002/cncr.28646

      Hyaluronan and hyaluronan-mediated motility receptor (HMMR) are associated with biochemical failure in patients with intermediate-grade prostate cancer, supporting a model whereby increased fragmented hyaluronan in tumors stimulates aggressive behavior through HMMR signaling.

    6. Head and Neck Disease
      Treatment and survival in 10,429 patients with localized laryngeal cancer: A population-based analysis (pages 1810–1817)

      Stephanie Misono, Schelomo Marmor, Bevan Yueh and Beth A. Virnig

      Article first published online: 17 MAR 2014 | DOI: 10.1002/cncr.28608

      Single-modality treatment for localized laryngeal cancer has become more common over time, in accordance with standard treatment guidelines. Unexpectedly, better survival was observed for patients whose treatment included local surgery than for those who received radiation only.

    7. Hematologic Malignancies
      Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program (pages 1818–1829)

      Chi Young Ok, Zijun Y. Xu-Monette, Alexandar Tzankov, Dennis P. O'Malley, Santiago Montes-Moreno, Carlo Visco, Michael B. Møller, Karen Dybkær, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, J. Han van Krieken, Maurilio Ponzoni, John P. Farnen, Miguel A. Piris, Jane N. Winter, L. Jeffrey Medeiros and Ken H. Young

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28664

      Compared with patients who have cyclin D1-negative diffuse large B-cell lymphoma (DLBCL), men are more commonly affected with cyclin D1-positive DLBCL and are significantly younger. There are no other significant differences in clinical presentation, pathologic features, overall survival, or progression-free survival between these 2 subgroups of patients with DLBCL; however, recognition of such subtypes is critical in the differential diagnosis of lymphoma.

    8. You have full text access to this OnlineOpen article
      The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States (pages 1830–1837)

      Loretta J. Nastoupil, Rajni Sinha, Michelle Byrtek, Xiaolei Zhou, Michael D. Taylor, Jonathan W. Friedberg, Brian K. Link, James R. Cerhan, Keith Dawson and Christopher R. Flowers

      Article first published online: 25 MAR 2014 | DOI: 10.1002/cncr.28659

      The authors present what, to their knowledge, is the largest published series to date of prospectively enrolled patients with previously untreated follicular lymphoma in the modern era examining the effectiveness of rituximab maintenance in clinical practice. With > 5 years of follow-up, it was found that, compared with observation, receipt of rituximab maintenance therapy was associated with significantly longer progression-free survival and time to next treatment in previously untreated patients with follicular lymphoma who achieved at least stable disease after rituximab-based induction therapy.

    9. You have full text access to this OnlineOpen article
      Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia (pages 1838–1846)

      Aristoteles Giagounidis, Ghulam J. Mufti, Pierre Fenaux, Mikkael A. Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Kuolung Hu, Paul Woodard, Allen S. Yang and Hagop M. Kantarjian

      Article first published online: 4 APR 2014 | DOI: 10.1002/cncr.28663

      Romiplostim increases platelet counts and decreases bleeding events and platelet transfusions in patients with low-risk/intermediate-1–risk myelodysplastic syndrome. The study drug has been stopped because of concerns regarding increased blast counts and progression to acute myeloid leukemia; survival and acute myeloid leukemia rates are similar, and follow-up is ongoing.

    10. Discipline

      Epidemiology
      Disparities of cancer incidence in Michigan's American Indians: Spotlight on breast cancer (pages 1847–1853)

      Emily L. Roen, Glenn E. Copeland, Noel L. Pinagtore, Rafael Meza and Amr S. Soliman

      Article first published online: 26 MAR 2014 | DOI: 10.1002/cncr.28589

      This study describes cancer trends among American Indians (AIs) in Michigan, USA, focusing on breast cancer, in a linked data set of Indian Health Service (IHS), tribal, and state cancer registry data adjusted for misclassification. This state-specific information will help formulate effective, tailored cancer prevention strategies to this population in Michigan. The data linkages methods used in this study are crucial for generating accurate rates and can be effective in addressing misclassification of the AI population and formulating cancer prevention strategies for AIs nationwide.

    11. Outcomes Research
      Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer (pages 1854–1862)

      Reshma Jagsi, Sarah T. Hawley, Paul Abrahamse, Yun Li, Nancy K. Janz, Jennifer J. Griggs, Cathy Bradley, John J. Graff, Ann Hamilton and Steven J. Katz

      Article first published online: 28 APR 2014 | DOI: 10.1002/cncr.28607

      Loss of paid employment after a diagnosis of breast cancer is common, often undesired, not restricted to the treatment period, and potentially related to the type of treatment administered. These findings should be considered when patients decide whether to receive adjuvant chemotherapy, particularly when the expected benefit is low.

    12. Shared decision-making and patient control in radiation oncology: Implications for patient satisfaction (pages 1863–1870)

      Jacob E. Shabason, Jun J. Mao, Eitan S. Frankel and Neha Vapiwala

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28665

      The results of the current study emphasize the importance of shared decision-making and patient-perceived control in management decisions within the field of radiation oncology, particularly as it relates to patient satisfaction and symptoms of psychological distress. Regardless of a patient's desire to be involved in the decision-making process, it is vital for the radiation oncology team to actively engage all patients in the clinical decision-making process.

    13. Quality of Life
      You have full text access to this OnlineOpen article
      Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma (pages 1871–1880)

      David Cella, Mellar P. Davis, Sylvie Négrier, Robert A. Figlin, M. Dror Michaelson, Andrew G. Bushmakin, Joseph C. Cappelleri, Rickard Sandin, Beata Korytowsky, Claudie Charbonneau, Ewa Matczak and Robert J. Motzer

      Article first published online: 13 MAR 2014 | DOI: 10.1002/cncr.28660

      Using phase 3 trial data for sunitinib versus interferon-α in treatment-naive patients with metastatic renal cell carcinoma, retrospective analyses characterized sunitinib-associated fatigue and its impact on patient-reported health-related quality of life. Patients reported worse fatigue during the first sunitinib cycle, but in subsequent consecutive cycles less fatigue was reported with no statistically significant worsening; provider-assessed fatigue did not appear to fully capture patient treatment experience.

    14. Quality of life changes during the pre- to postdiagnosis period and treatment-related recovery time in older women with breast cancer (pages 1881–1889)

      Angela M. Stover, Deborah K. Mayer, Hyman Muss, Stephanie B. Wheeler, Jessica C. Lyons and Bryce B. Reeve

      Article first published online: 19 MAR 2014 | DOI: 10.1002/cncr.28649

      Women aged 65 years and older who are diagnosed with breast cancer should be counseled that survivors within 6 months of diagnosis are vulnerable to health-related quality of life (HRQOL) declines, compared to older women without breast cancer, but decrements generally wane after 12 months. Similar HRQOL declines occurred across groups receiving breast-conserving surgery, breast-conserving surgery plus radiation, and mastectomy, suggesting that older women choosing any one of these treatment modalities fare equally well for HRQOL.

    15. Symptom Control and Palliative Care
      North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study (pages 1890–1897)

      Alexis D. Leal, Rui Qin, Pamela J. Atherton, Paul Haluska, Robert J. Behrens, Charles H. Tiber, Patanit Watanaboonyakhet, Matthias Weiss, Paul T. Adams, Travis J. Dockter, Charles L. Loprinzi and for the Alliance for Clinical Trials in Oncology

      Article first published online: 11 MAR 2014 | DOI: 10.1002/cncr.28654

      Glutathione is not effective in preventing paclitaxel/carboplatin-induced peripheral neuropathy. In addition, it does not appear to interfere with the antitumor activity of paclitaxel/carboplatin.

    16. Translational Research
      Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas (pages 1898–1907)

      Alec E. Vaezi, Gerold Bepler, Nikhil R. Bhagwat, Agnes Malysa, Jennifer M. Rubatt, Wei Chen, Brian L. Hood, Thomas P. Conrads, Lin Wang, Carolyn E. Kemp and Laura J. Niedernhofer

      Article first published online: 1 APR 2014 | DOI: 10.1002/cncr.28643

      The monoclonal antibody 8F1 has been used to determine ERCC1 levels to predict platinum efficacy and as a prognostic marker for the survival of patients with malignancies. The results of the current study demonstrate that 8F1 detects 2 unrelated proteins, ERCC1 and choline phosphate cytidylyltransferase-α (CCTα), and that CCTα is prognostic for survival in patients with lung and head and neck squamous cell carcinomas.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Cancer survivorship: Is there a role for cancer survivor clinics? (pages 1908–1909)

      Ernesto Zanet, Mariagrazia Michieli and Umberto Tirelli

      Article first published online: 11 MAR 2014 | DOI: 10.1002/cncr.28658

  6. Erratum

    1. Top of page
    2. CancerScope
    3. Commentary
    4. Review Article
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Erratum: Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers (page 1910)

      Article first published online: 6 MAR 2014 | DOI: 10.1002/cncr.28666

      This article corrects:

      Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers

      Vol. 120, Issue 7, 1068–1075, Article first published online: 30 DEC 2013

SEARCH

SEARCH BY CITATION